Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 21;512(7514):324-7.
doi: 10.1038/nature13387. Epub 2014 Jun 25.

A Vaccine Targeting Mutant IDH1 Induces Antitumour Immunity

Affiliations

A Vaccine Targeting Mutant IDH1 Induces Antitumour Immunity

Theresa Schumacher et al. Nature. .

Abstract

Monoallelic point mutations of isocitrate dehydrogenase type 1 (IDH1) are an early and defining event in the development of a subgroup of gliomas and other types of tumour. They almost uniformly occur in the critical arginine residue (Arg 132) in the catalytic pocket, resulting in a neomorphic enzymatic function, production of the oncometabolite 2-hydroxyglutarate (2-HG), genomic hypermethylation, genetic instability and malignant transformation. More than 70% of diffuse grade II and grade III gliomas carry the most frequent mutation, IDH1(R132H) (ref. 3). From an immunological perspective, IDH1(R132H) represents a potential target for immunotherapy as it is a tumour-specific potential neoantigen with high uniformity and penetrance expressed in all tumour cells. Here we demonstrate that IDH1(R132H) contains an immunogenic epitope suitable for mutation-specific vaccination. Peptides encompassing the mutated region are presented on major histocompatibility complexes (MHC) class II and induce mutation-specific CD4(+) T-helper-1 (TH1) responses. CD4(+) TH1 cells and antibodies spontaneously occurring in patients with IDH1(R132H)-mutated gliomas specifically recognize IDH1(R132H). Peptide vaccination of mice devoid of mouse MHC and transgenic for human MHC class I and II with IDH1(R132H) p123-142 results in an effective MHC class II-restricted mutation-specific antitumour immune response and control of pre-established syngeneic IDH1(R132H)-expressing tumours in a CD4(+) T-cell-dependent manner. As IDH1(R132H) is present in all tumour cells of these slow-growing gliomas, a mutation-specific anti-IDH1(R132H) vaccine may represent a viable novel therapeutic strategy for IDH1(R132H)-mutated tumours.

Comment in

Similar articles

See all similar articles

Cited by 201 articles

See all "Cited by" articles

References

    1. Science. 2013 May 3;340(6132):626-30 - PubMed
    1. J Exp Med. 1996 Jun 1;183(6):2635-44 - PubMed
    1. Am J Pathol. 2009 Apr;174(4):1149-53 - PubMed
    1. J Exp Med. 2010 Mar 15;207(3):637-50 - PubMed
    1. Science. 2013 May 3;340(6132):622-6 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback